Celsion Provides Summary of Research and Development Day Held on October 12, 2017
October 18, 2017 08:30 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided a summary of GEN-1 immunotherapy-related presentations...
Celsion Provides Summary of Research and Development Day Held on Thursday, October 12, 2017
October 17, 2017 08:30 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology development company, today provided a summary of ThermoDox® related presentations made during...
Celsion Announces Publication of the HEAT Study Manuscript in the High Impact Journal, Clinical Cancer Research
October 16, 2017 08:30 ET
|
Celsion Corporation
80+ Month Overall Survival (HR = 0.63, Pvalue = 0.02) Discussed in the 285 Patient Sub-group Treated with ThermoDox® plus Standardized Radiofrequency Ablation (sRFA) Ongoing Phase III OPTIMA Study to...
Celsion to Host Research and Development (R&D) Day on Thursday, October 12, 2017
October 12, 2017 11:02 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology development company, today announced that it will host a Research and Development (R&D) Day...
Celsion Corporation Announces Gross Proceeds of $15.6 Million from the Exercise of Existing Common Stock Warrants
October 04, 2017 13:45 ET
|
Celsion Corporation
Financing Accomplished with Minimal New Equity Issuance Operating Runway Extended through 2018 LAWRENCEVILLE, N.J., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the “Company”)...
Celsion to Host Research and Development Update October 12, 2017
October 04, 2017 09:00 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology development company, today announced that it will host a Research and Development (R&D) Day...
Celsion Announces Final Clinical and Translational Research Data from its OVATION Study at the AACR Special Conference on Ovarian Cancer
October 03, 2017 09:00 ET
|
Celsion Corporation
100% Disease Control; 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated in Four Dose-Escalating Cohorts Clear Evidence of Biological Activity Including...
Celsion Provides Update on ThermoDox® in the Phase III OPTIMA Study of Primary Liver Cancer
September 27, 2017 09:00 ET
|
Celsion Corporation
OPTIMA Study Enrollment is Approaching 70% Independent Data Monitoring Committee Provided Unanimous Recommendation to Continue Study in August 2017 Investigators Meetings in Thailand and China...
Celsion Announces Presentation of OVATION Study Findings at the Upcoming AACR Special Conference
August 24, 2017 09:30 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided an update on its OVATION Study, a Phase Ib dose...
Celsion Corporation Reports Second Quarter 2017 Financial Results and Provides Business Update
August 15, 2017 08:00 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the quarter and six month period...